Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
Argenx takes a step towards convenience
The group is taking a subcutaneous formulation of efgartigimod to regulators, but is keeping quiet about price.
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Another failure heaps more pressure on Novartis
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
Investors back Quell’s Treg approach
Quell should soon join Sangamo in the clinic, while a number of engineered Treg players are at the preclinical stage.
Go or no go? Argenx's December showdown
2021 rounds off with key FDA decisions for Argenx, Calliditas and Merck, while Novartis will be hoping for an early Leqvio verdict.
